Aptevo Therapeutics Inc. (APVO)
Last updated: 2026-10-24 21:09:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Aptevo Therapeutics Inc. (APVO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.61, with a market capitalization of $2.91M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.37 to $28.44. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$2.91M | |
$1.61 | |
$52,102,512.00 | |
$1.37 | |
$1.61 | |
7.08K | |
93.95K | |
-- | |
$28.44 | |
$1.37 | |
-- | |
-- |
Aptevo Therapeutics Inc. (APVO) Latest Closing Stock Price
Aptevo Therapeutics Inc. (APVO) last closed at $1.61 as of 2026-10-23 23:31:00, unchanged from the previous close of $1.61.
During the latest regular trading session, APVO traded between $1.37 and $52,102,512.00, with a volume of 7.08K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Aptevo Therapeutics Inc. (APVO) 7-Day Stock Price Change
Over the past seven days, Aptevo Therapeutics Inc. (APVO) moved from $1.70 to $1.61, representing a decline of 5.29% ($0.09).
The stock traded between $1.57 and $1.74 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 12.16 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
APVO 52-Week Price Position
Position in Range: 0.9%
APVO is currently trading at $1.61, placing it 0.9% of the way from its 52-week low of $1.37 to its 52-week high of $28.44. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Aptevo Therapeutics Inc. (APVO)?
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, CD3xCD123, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Aptevo Therapeutics Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 33 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Aptevo Therapeutics Inc. (APVO) Stock on MEXC
Eligible investors can buy real shares of Aptevo Therapeutics Inc. (APVO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Aptevo Therapeutics Inc. (APVO) stock price today?
2.Is APVO stock going up or down today?
3.What is APVO pre-market price?
4.What is APVO after-hours price?
5.Is APVO stock trading now?
6.Where does APVO sit relative to its 52-week high and low?
7.What sector is Aptevo Therapeutics Inc. in?
8.What is Aptevo Therapeutics Inc.'s market capitalization and where is it listed?
9.How is APVO valued in terms of P/E ratio and EPS?
10.Does Aptevo Therapeutics Inc. pay a dividend?
Explore More US Stocks
Search Stocks
APVO Stock Calculator
Estimate the value between APVO shares and USD.
APVO Shares to USD
1.00 APVO shares = 1.61 USD
Calculations are estimates based on the latest available price and are for reference only.


